Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 67.5%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large drop in short interest in the month of August. As of August 15th, there was short interest totaling 60,800 shares, adropof67.5% from the July 31st total of 187,000 shares. Based on an average daily trading volume, of 221,800 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily trading volume, of 221,800 shares, the days-to-cover ratio is presently 0.3 days.

Astellas Pharma Stock Up 1.3%

OTCMKTS:ALPMY opened at $11.09 on Wednesday. Astellas Pharma has a 1 year low of $8.37 and a 1 year high of $12.99. The stock has a 50-day moving average price of $10.35 and a two-hundred day moving average price of $9.88. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.13 and a quick ratio of 0.85.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.26. Astellas Pharma had a return on equity of 19.76% and a net margin of 4.34%.The company had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.20 billion. As a group, sell-side analysts expect that Astellas Pharma will post 0.42 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.